ライフサイエンスコーパス: brain metastases

1 le which was CNS penetrant in order to treat brain metastases.

2 py in patients with untreated or progressive brain metastases.

3 ted 20% of patients with cancer will develop brain metastases.

4 -life endpoints into trials of patients with brain metastases.

5 or retrospective study focusing on melanoma brain metastases.

6 secondary ALK kinase domain mutations and/or brain metastases.

7 r cohort and refine it integrating number of brain metastases.

8 for use in clinical trials of treatment for brain metastases.

9 what metabolic changes benefit breast cancer brain metastases.

10 ligand (123)I-DPA-713 for early detection of brain metastases.

11 tral radiological review of individuals with brain metastases.

12 rst-line treatment for gliomas and recurrent brain metastases.

13 us toward new perspectives in understanding brain metastases.

14 acardially into female BALB/c mice to induce brain metastases.

15 tastatic breast cancer eventually developing brain metastases.

16 rt tumor and confirmed partial resolution of brain metastases.

17 s in a rodent model of breast adenocarcinoma brain metastases.

18 of life are major concerns for patients with brain metastases.

19 rove the targeting of immune cell therapy of brain metastases.

20 ived from human cell lines or from patients' brain metastases.

21 inib has not been studied in active melanoma brain metastases.

22 Antitumour activity was also recorded in brain metastases.

23 was not associated with an increased risk of brain metastases.

24 cell lines for their ability to develop into brain metastases.

25 patients with EGFR-mutant NSCLC who develop brain metastases.

26 (GPA), a prognostic index for patients with brain metastases.

27 arnofsky performance score and the number of brain metastases.

28 r improve outcomes in patients with melanoma brain metastases.

29 d stratify clinical trials for patients with brain metastases.

30 ubbles can improve outcomes in breast cancer brain metastases.

31 he treatment of HER2-amplified breast cancer brain metastases.

32 y of this drug specifically in patients with brain metastases.

33 Two patients had previously treated brain metastases.

34 se with melanoma and untreated, asymptomatic brain metastases.

35 ificantly to the management of patients with brain metastases.

36 ary tumor growth and abrogating formation of brain metastases.

37 ndependence after surgery or radiosurgery of brain metastases.

38 estigational approaches in the management of brain metastases.

39 n and treatment of symptomatic breast cancer brain metastases.

40 despite increasing the invasive histology of brain metastases.

41 tracranial disease of 14 patients with known brain metastases.

42 n patients with NSCLC and previously treated brain metastases.

43 and memory in patients with newly diagnosed brain metastases.

44 trastuzumab or those who have HER2-negative brain metastases.

45 ose with squamous cell histology and treated brain metastases.

46 ) and HER-2, in patients with HER-2-positive brain metastases.

47 and whether the trial excluded patients with brain metastases.

48 re accumulating for targeted agents to treat brain metastases.

49 ghly refractory patients with HER-2-positive brain metastases.

50 -2 and EGFR was also observed in a subset of brain metastases.

51 atus, extracranial metastases, and number of brain metastases.

52 months from the time of initial treatment of brain metastases.

53 with non-small-cell lung cancer (NSCLC) and brain metastases.

54 free survival were measured from the date of brain metastases.

55 alternative therapies for the management of brain metastases.

56 patients with newly diagnosed and untreated brain metastases.

57 in patients with BRAF(V600)-mutant melanoma brain metastases.

58 alteration data for patients with NSCLC and brain metastases.

59 brain radiotherapy (WBRT) each year to treat brain metastases.

60 2006 and 2014 with NSCLC and newly diagnosed brain metastases.

61 ve longer and thus are at increased risk for brain metastases.

62 ls in the murine brain and in human melanoma brain metastases.

63 ry for a response to the antibodies in these brain metastases.

64 : the development of central nervous system (brain) metastases.

65 ohort study of 293 patients with cancer with brain metastases (104 with therapeutic enoxaparin and 18

66 through 2014 with NSCLC and newly diagnosed brain metastases (1521 adenocarcinoma and 665 nonadenoca

67 ed 52 patients with untreated or progressive brain metastases (18 with melanoma, 34 with NSCLC), and

68 More nivolumab-treated patients had brain metastases (20% v 14%) and increased lactate dehyd

69 s 17% (n=603), with subgroup ORR as follows: brain metastases (26 of 213 [12%]), ECOG performance sta

70 s population included 321 (7%) patients with brain metastases, 582 (13%) with Eastern Cooperative Onc

71 and HER2-negative primary breast cancers and brain metastases, (89)Zr-pertuzumab PET/CT suggested tha

72 However, number of brain metastases-a highly relevant clinical variable-is

73 tor 2 (HER-2)-positive breast cancer develop brain metastases; a subset progress in the CNS despite s

74 diosurgery or surgery of a limited number of brain metastases, adjuvant WBRT reduces intracranial rel

75 ndings suggest that for patients with 1 to 3 brain metastases amenable to radiosurgery, SRS alone may

76 f the brain because of the high incidence of brain metastases among patients with HER2-positive advan

77 Patients with stable brain metastases and an Eastern Cooperative Oncology Gro

78 f 94 patients with retrospectively confirmed brain metastases and at least one post-baseline MRI or C

79 Her-2 expression trends from resected human brain metastases and data from an experimental brain met

80 patients with EGFR-mutant NSCLC who develop brain metastases and have not received EGFR-TKI.

81 nstitutions with EGFR-mutant NSCLC developed brain metastases and met inclusion criteria for the stud

82 portion and median survival of patients with brain metastases and newly diagnosed breast cancer.

83 nt of metastatic melanoma are active against brain metastases and offer new opportunities to improve

84 GR cells had significantly more experimental brain metastases and shorter overall survival than did m

85 tes in the subclinical perivascular stage of brain metastases and show that they are inhibitable by p

86 s, we review the state of clinical trials of brain metastases and suggest a consensus recommendation

87 he inclusion of these endpoints in trials of brain metastases and the methods by which these measures

88 lity in decreasing the rapid growth of solid brain metastases and vasogenic edema in patients with ad

89 wo patients who had 83 previously irradiated brain metastases and who underwent (18)F-FDOPA PET becau

90 ts who have received prior therapy for their brain metastases and whose CNS disease is radiographical

91 ample, 66% had primary brain tumors, 27% had brain metastases, and 8% underwent prophylactic cranial

92 arise evidence for the treatment of melanoma brain metastases, and discuss the rationale and evidence

93 yroid dysfunction or diabetes, had no active brain metastases, and had not received previous immune c

94 1 is up-regulated on vessels associated with brain metastases, and if so, whether VCAM-1-targeted MRI

95 of 0 to 1, adequate organ function, treated brain metastases, and no recent vascular events or bleed

96 metastatic melanoma, melanoma with untreated brain metastases, and non-melanoma solid tumours.

97 h responses noted in patients with melanoma, brain metastases, and other solid tumours.

98 rsive partitioning analysis class, number of brain metastases, and radioresistant histology.

99 noma, expression of HLA*A0201, an absence of brain metastases, and suitability for high-dose interleu

100 Performance Status (KPS), gender, status of brain metastases, and the status of primary lung cancer.

101 Brain metastases are a serious obstacle in the treatment

102 Brain metastases are a significant cause of morbidity an

103 Brain metastases are among the most feared complications

104 Brain metastases are common and are usually detected by

105 Brain metastases are difficult to treat and mostly devel

106 Brain metastases are frequently treated with radiation.

107 Glioblastomas and brain metastases are highly proliferative brain tumors w

108 ies for treating breast cancer patients with brain metastases are inefficient.

109 Medical therapies for refractory brain metastases are neither well-studied nor establishe

110 Because brain metastases are responsible for life-threatening sy

111 Miliary brain metastases are very rarely described in the litera

112 PCI significantly reduced the probability of brain metastases as first site of failure (7.8% at 5 yea

113 nt or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at scr

114 ted or locally treated neurologically stable brain metastases at baseline.

115 t of patients with follow-up had progressive brain metastases at death, and repeated interventions fo

116 ed to identify predictors of the presence of brain metastases at diagnosis and factors associated wit

117 estimates of the incidence and prognosis of brain metastases at diagnosis of breast cancer are lacki

118 and 2013 for whom the presence or absence of brain metastases at diagnosis was known.

119 survivals of patients with breast cancer and brain metastases at the time of cancer diagnosis.

120 We identified 968 patients with brain metastases at the time of diagnosis of breast canc

121 Patients with breast cancer and brain metastases at the time of diagnosis were identifie

122 etastases, defined as new and/or progressive brain metastases at the time of study entry; and those w

123 he incidence and prognosis for patients with brain metastases at time of diagnosis of breast cancer.

124 afts (PDXs) of HER2-expressing breast cancer brain metastases (BCBM), and their use for the identific

125 Brain metastases (BM) are a devastating consequence of b

126 Brain metastases (BM) are the most common intracranial t

127 eutics for treatment of cancer patients with brain metastases, BMBC in particular.

128 Brain metastases (BMs) are the most common malignancy of

129 Brain metastases (BMs) occur in 10% to 20% of adult pati

130 Patients with breast cancer (BrCa) brain metastases (BrM) have limited therapeutic options.

131 gnetic resonance imaging (MRI) to screen for brain metastases, but rather should have a low threshold

132 hage is frequently observed in patients with brain metastases, but that therapeutic anticoagulation d

133 ents with BRAF(V600)-mutant melanoma without brain metastases, but the median duration of response wa

134 frequently in patients with cancer who have brain metastases, but there is limited evidence supporti

135 prevented the outgrowth of 231-BR-HER2 large brain metastases by 73%.

136 Brain metastases commonly develop in patients with melan

137 miRNA-768-3p was reduced in patient brain metastases compared to normal brain tissue and was

138 tissue and was lower in patient tissue from brain metastases compared to same-patient primary tumour

139 ce of extracranial metastases, and number of brain metastases, confirming the original Lung-GPA.

140 st cancer, the incidence of life-threatening brain metastases continues to increase in some of these

141 Ib or IV; chemotherapy naive; no symptomatic brain metastases; deemed unsuitable for chemotherapy bec

142 lly stable at study entry; those with active brain metastases, defined as new and/or progressive brai

143 e key populations: those with treated/stable brain metastases, defined as patients who have received

144 ved drugs, sunitinib and dasatinib, prohibit brain metastases derived from breast cancer, addressing

145 actors found in 1833 patients with NSCLC and brain metastases diagnosed between 1985 and 2005: patien

146 Because these brain metastases do not respond to therapy, they are fre

147 We diagnosed the lesions as disseminated brain metastases due to lung cancer.

148 HER2-positive breast cancer with progressive brain metastases during or after treatment with trastuzu

149 In 39 of 45 brain metastases eligible for dynamic analysis, a wide r

150 r day) in four patient cohorts with melanoma brain metastases enrolled from 32 hospitals and institut

151 Brain metastases expression changes in 127 genes within

152 PCI is effective in preventing brain metastases following this aggressive trimodality a

153 stigated in patients with breast cancer with brain metastases for their ability to reduce CSFTC count

154 brain imaging can identify clinically silent brain metastases; frequency of detection might have incr

155 the emergence of resistance mutations and of brain metastases frequently causes relapse in patients.

156 Patients with newly diagnosed brain metastases from 1996 to 2013 were identified.

157 Patients with brain metastases from ALK-rearranged NSCLC treated with

158 A total of 90 patients with brain metastases from ALK-rearranged NSCLC were identifi

159 ular morphologic changes during treatment of brain metastases from breast cancer and if serial quanti

160 Of 124 archival resected brain metastases from breast cancer patients, 36.2% over

161 nti-miR10b into mice bearing lung, bone, and brain metastases from breast cancer resulted in selectiv

162 hs after initiation of lapatinib therapy for brain metastases from breast cancer.

163 (+) astrocytes were also identified in human brain metastases from eight craniotomy specimens and in

164 we show that outgrowth of large experimental brain metastases from human 231-BR or murine 4T1-BR brea

165 Clinically, we showed that brain metastases from human breast cancer patients expre

166 Finally, we show that the brain metastases from lung carcinoma and other carcinoma

167 tor pembrolizumab in patients with untreated brain metastases from melanoma or non-small-cell lung ca

168 ) and dexamethasone are widely used to treat brain metastases from non-small cell lung cancer (NSCLC)

169 rain radiotherapy required to treat multiple brain metastases from non-small-cell lung cancer when hi

170 rgery or radiosurgery of a limited number of brain metastases from solid tumors may negatively impact

171 2009, we enrolled patients with melanoma and brain metastases from ten US centres who were older than

172 older with melanoma or NSCLC with untreated brain metastases from the Yale Cancer Center.

173 ble analysis of the breast-GPA and number of brain metastases (> three v </= three), both were indepe

174 gible patients were those with HER2-positive brain metastases (>/= 1 cm in longest dimension) who exp

175 l lesions in the liver and lungs whereas the brain metastases had nearly resolved.

176 Historically, the prognosis of patients with brain metastases has been poor; however, with new therap

177 s' ability to predict survival in NSCLC with brain metastases has improved significantly.

178 The incidence of brain metastases has increased as a result of improved s

179 Historically, patients with brain metastases have been excluded from most clinical t

180 Brain metastases have been shown to induce a robust glia

181 Historically, patients with brain metastases have been understudied, because of rest

182 trials in cancer, patients with symptomatic brain metastases have commonly been excluded from partic

183 with non-small-cell lung cancer (NSCLC) and brain metastases have previously been excluded from tria

184 hes to estimating prognosis of patients with brain metastases highlight the importance of tailoring t

185 sitive association between disease stage and brain metastases highlights a patient subset that may po

186 n of extracranial disease control, number of brain metastases, histology, maximal resection cavity di

187 RAF(V600)-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib pl

188 Results: Forty-five brain metastases in 30 patients were included.

189 Forty-five brain metastases in 30 patients were included.

190 in patients with HER2-positive breast cancer brain metastases in a multicenter, phase II open-label t

191 ways as possible targets in the treatment of brain metastases in breast cancer.

192 ons regarding the inclusion of patients with brain metastases in clinical trials, as part of a broade

193 d progression criteria for the assessment of brain metastases in clinical trials.

194 he inclusion of patients with treated/stable brain metastases in clinical trials.

195 reader 4; P = .012) metastases and revealed brain metastases in five of 51 (10%) patients.

196 inhibitors (TKIs) are treatment options for brain metastases in patients with EGFR-mutant non-small-

197 The incidence of brain metastases in patients with lung cancer has increa

198 Pembrolizumab shows activity in brain metastases in patients with melanoma or NSCLC with

199 rradiation not only reduces the incidence of brain metastases in patients with SCLC and with non-meta

200 rgery or radiosurgery of a limited number of brain metastases in patients with stable solid tumors.

201 wo-part series, we review clinical trials of brain metastases in relation to measures of clinical ben

202 ing combinatorial regimens can treat HER2(+) brain metastases in this model.

203 sequences of detection of new or progressive brain metastases in trials mainly exploring the extra-CN

204 ed against the potential benefit in terms of brain metastases incidence and survival.

205 potential pathways to target ALK-rearranged brain metastases, including next generation ALK inhibito

206 val (OS) in patients with breast cancer with brain metastases, including the breast graded prognostic

207 Earlier detection of brain metastases is critical for improved treatment.

208 We conclude that the T-cell response to brain metastases is not a surrogate of local tumor invas

209 The poor prognosis for patients with brain metastases is thought to be largely due to the pre

210 eatment led to regression of EML4-ALK-driven brain metastases, leading to prolonged mouse survival, i

211 that are focused on other tumors, including brain metastases, leptomeningeal metastases, spine tumor

212 racking; (3) outcome prediction in epilepsy, brain metastases, lumbar spinal stenosis, lumbar disc he

213 In this view, brain metastases may be conceptualized as progressive on

214 The treatment of multiple brain metastases (MBM) from melanoma is controversial an

215 ith mild vasogenic edema and four additional brain metastases measuring 4 to 9 mm in size.

216 that a subset of patients with asymptomatic brain metastases might be appropriately entered into pha

217 atments and thus effective interventions for brain metastases might be developed more promptly.

218 examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ

219 owth and improve survival in a breast cancer brain metastases model.

220 Therapeutic outcomes for patients with brain metastases need to improve.

221 In patients with melanoma and untreated brain metastases, nine of ten patients had reductions in

222 organoids could be established directly from brain metastases not typically amenable to in vitro cult

223 ALK-positive non-small-cell lung cancer with brain metastases now have the potential to achieve a pro

224 Brain metastases occur in more than one-third of metasta

225 uzumab most likely fails in the treatment of brain metastases of breast cancer because of poor CNS pe

226 or (PEDF) is downregulated in resected human brain metastases of breast cancer compared with primary

227 ormal breast tissues and stromal cultures of brain metastases of breast cancer had similar effects as

228 e against glioblastoma but generally fail in brain metastases of breast cancer.

229 Patients with one to three brain metastases of solid tumors (small-cell lung cancer

230 REP1 accumulation in a large number of human brain metastases of various solid tumors, including NSCL

231 HER2 inhibitors in the majority of patients, brain metastases often develop.

232 Patients were excluded if they had active brain metastases or active autoimmune disease requiring

233 ate treatment is influenced by the number of brain metastases, overall patient performance status and

234 in some patients with advanced melanoma and brain metastases, particularly when metastases are small

235 GFR and PTEN alteration as the breast cancer brain metastases patients.

236 However, patients with asymptomatic brain metastases pose an increasingly frequent challenge

237 ed the outgrowth of established experimental brain metastases, prolonging the survival of metastases-

238 The Quality of Life after Treatment for Brain Metastases (QUARTZ) study is a non-inferiority, ph

239 n (r(2) = 0.921, P < 0.001) and incidence of brain metastases (r(2) = 0.708, P < 0.001).

240 s of search terms and synonyms for melanoma, brain metastases, radiation, chemotherapy, immunotherapy

241 The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an internati

242 for the correct identification of recurrent brain metastases reached 78% using TBR(max) (area under

243 metastasis and were selectively enriched in brain metastases relative to paired primary lung tumors.

244 tat3 correlated with attenuation of Cav-1 in brain metastases relative to primary tumors.

245 , its role in the treatment of patients with brain metastases remains controversial.

246 Brain metastases represent the greatest clinical challen

247 igh-risk primary BC subgroups for developing brain metastases, represented by genetic alterations in

248 Evidence-based management of brain metastases represents an evolving field of active

249 , CSFTC) of nine breast cancer patients with brain metastases revealed dynamic changes in tumor cell

250 ical to distinguish recurrent or progressive brain metastases (RPBM) from late or delayed radiation i

251 erlotinib in patients with NSCLC and treated brain metastases seems to be safe and is associated with

252 s Patients with treated or clinically stable brain metastases should be routinely included in trials

253 Patients with brain metastases should receive appropriate local therap

254 es whether patients with a limited number of brain metastases should undergo whole brain radiation th

255 cal review of trials specifically addressing brain metastases shows key issues that could prevent acc

256 had complete resection of one, two, or three brain metastases significantly lowers local recurrence c

257 ermines the ability of a cancer cell to form brain metastases successfully.

258 ld enable substantially earlier detection of brain metastases than the current clinical approach of g

259 melanomas produce site-specific experimental brain metastases that reflect clinical reality.

260 s is the first description of a patient with brain metastases that were characterised by restricted d

261 Among patients with 1 to 3 brain metastases, the use of SRS alone, compared with SR

262 ger following the diagnosis and treatment of brain metastases, there has been rising concern about tr

263 of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plu

264 ailable specimens of matched fresh breast-to-brain metastases tissue and derived cells from patients

265 ge was conferred by the ability of breast-to-brain metastases to take up and catabolize GABA into suc

266 However, the response of brain metastases to these drugs is poor, and it is hypot

267 status [0 vs 1-2] and presence or absence of brain metastases) to oral ceritinib 750 mg per day faste

268 gnificantly larger fraction of breast cancer brain metastases tumor tissue compared with samples from

269 abase of 3,940 patients with newly diagnosed brain metastases underwent univariate and multivariate a

270 NSCLC patients with brain metastases unsuitable for surgical resection or st

271 Treatment of patients with multiple brain metastases using a single-isocenter volumetric mod

272 Prognostic factors for patients with brain metastases vary by diagnosis, and for each diagnos

273 Median survival among the entire cohort with brain metastases was 10.0 months.

274 Median OS after development of brain metastases was 49.5 months (95% CI, 29.0 months to

275 key considerations for patients with active brain metastases was developed.

276 ratified by EGFR mutation type and status of brain metastases, was done centrally using a validated n

277 Patients with brain metastases were allowed to enrol only if the lesio

278 and no history of TKIs before development of brain metastases were associated with improved survival

279 ses at death, and repeated interventions for brain metastases were common.

280 (89)Zr-pertuzumab PET/CT suggested that the brain metastases were HER2-positive.

281 (EGFR) mRNA levels in a cohort of 12 frozen brain metastases were increased up to 5- and 9-fold, res

282 s (n = 40) on MRI after radiation therapy of brain metastases were investigated with dynamic (18)F-FE

283 Patients with untreated brain metastases were not permitted to enrol in these tr

284 tions in North America, patients with 1 to 3 brain metastases were randomized to receive SRS or SRS p

285 Patients with one to three newly diagnosed brain metastases were randomly assigned using a standard

286 Historically, brain metastases were rarely investigated because patien

287 Brain metastases were strongly associated with more adva

288 bsequent growth of bone metastases, although brain metastases were subject to rebound growth after th

289 izumab treatment, histology, and presence of brain metastases, were allocated (by computer-generated

290 specific role in spinal cord compression and brain metastases, where improved analgesia is a secondar

291 All patients had developed brain metastases while receiving trastuzumab; 37 had pro

292 s a single-arm phase II study of HA-WBRT for brain metastases with prespecified comparison with a his

293 and had a complete resection of one to three brain metastases (with a maximum diameter of the resecti

294 BRAF(V600E)-positive, asymptomatic melanoma brain metastases, with no previous local brain therapy,

295 F(V600D/K/R)-positive, asymptomatic melanoma brain metastases, with or without previous local brain t

296 (V600D/E/K/R)-positive, symptomatic melanoma brain metastases, with or without previous local brain t

297 BRAF(V600E)-positive, asymptomatic melanoma brain metastases, with previous local brain therapy, and

298 may have efficacy against a wide variety of brain metastases without CNS toxicity.

299 Patients with newly diagnosed brain metastases without prior local therapy and (18)F-F

300 Methods: Patients with newly diagnosed brain metastases without prior local therapy and (18)F-F